Back to List

Title:


Author:
Date:
Source:

Efficacy and Safety of Topiramate for the
Treatment of Chronic Migraine: A Randomized,
Double-Blind, Placebo-Controlled Trial
Silberstein SD, Lipton RB, Dodick, DW, et al.
Posted: April 2007  
Headache 2007;47:170-180

Objective:   To evaluate the efficacy and safety of topiramate (100 mg/day) compared with placebo for the treatment of chronic migraine.

Methods:   This was a randomized, placebo-controlled, parallel-group, multicenter study consisting of 16 weeks of double-blind treatment. Subjects aged 18 to 65 years with 15 or more headache days per month, at least half of which were migraine/migrainous headaches, were randomized 1:1 to either topiramate 100 mg/day or placebo.

Conclusions:   Topiramate treatment at daily doses of approximately 100 mg resulted in statistically significant improvements compared with placebo in mean monthly migraine/migrainous and migraine headache days. Topiramate is safe and generally well tolerated in this group of subjects with chronic migraine, a burdensome condition with important unmet treatment needs. Safety and tolerability of topiramate were consistent with experience in previous clinical trials involving the drug.